Search
VPM1002
go.drugbank.com/drugs/DB15801InvestigationalBCG versions due to the lack of the RD2 genome segment. … VPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other
Bethanechol
go.drugbank.com/drugs/DB01019ApprovedBethanechol is a synthetic ester that was initially synthesized in 1935. … [A232905,L32539] As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the parasympathetic nervous
Asapiprant
go.drugbank.com/drugs/DB20492InvestigationalAsapiprant has a monoisotopic molecular weight of 501.16 Da. … Asapiprant is a small molecule drug.
Alofanib
go.drugbank.com/drugs/DB20918InvestigationalAlofanib has a monoisotopic molecular weight of 413.07 Da. … Alofanib is a small molecule drug. The usage of the INN stem '-anib' in the name indicates that Alofanib is a angiogenesis inhibitor.
Cystine
go.drugbank.com/drugs/DB00138ApprovedInvestigationalNutraceuticalWithdrawnA covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.
Aminosalicylic acid
go.drugbank.com/drugs/DB00233ApprovedInvestigationalAn antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.
rsPSMA Vaccine
go.drugbank.com/drugs/DB06361ApprovedWithdrawnrsPSMA Vaccine is a subunit vaccine based on a novel rsPSMA protein that represents the entire extracellular domain of PSMA (Schulke et al., PNAS 100:12590, 2003). … Prostate-specific membrane antigen (PSMA) is an ∼100 kDa transmembrane glycoprotein that is abundantly and preferentially expressed in prostate cancer, including recurrent and hormone-refractory cases.
Fosdenopterin
go.drugbank.com/drugs/DB16628Approved[A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity. … In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A.
Plerixafor
go.drugbank.com/drugs/DB06809ApprovedInvestigationalPlerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. … [A7118,L45678] As an inhibitor of CXCR4, plerixafor blocks the binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1α).
Digoxin Immune Fab (Ovine)
go.drugbank.com/drugs/DB00076ApprovedDigoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.